Pashna N Munshi
Overview
Explore the profile of Pashna N Munshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Munshi P, Olin R, Wall S, McCurdy S, Al-Juhaishi T, Baker J, et al.
Transplant Cell Ther
. 2025 Feb;
PMID: 39961473
Geriatric assessment (GA) may identify vulnerabilities and promote risk-stratification in older adults predisposed to toxicities after autologous (auto), allogeneic (allo) hematopoietic cell transplantation (HCT) and chimeric antigen T-cell therapies (CAR...
2.
Hashmi H, Kumar A, Kharfan-Dabaja M, Munshi P, Inamoto Y, DeFilipp Z, et al.
Transplant Cell Ther
. 2024 Apr;
30(8):750-759.
PMID: 38615990
Chimeric antigen receptor T cell therapy (CAR-T) has revolutionized the management of relapsed and/or refractory multiple myeloma (RRMM). However, CAR-T treatment failure is not uncommon and remains a major therapeutic...
3.
Munshi P, McCurdy S
Am J Hematol
. 2024 Feb;
99(5):922-937.
PMID: 38414188
Allogeneic hematopoietic cell transplantation (HCT) is no longer exclusively for the young. With an aging population, development of non-intensive remission-inducing strategies for hematologic malignancies, and novel graft-versus-host disease-prevention platforms, an...
4.
Ustun C, Chen M, Kim S, Auletta J, Batista M, Battiwalla M, et al.
Bone Marrow Transplant
. 2023 Oct;
59(1):76-84.
PMID: 37903992
Post-transplant cyclophosphamide (PTCy) is increasingly used to reduce graft-versus-host disease after hematopoietic cell transplantation (HCT); however, it might be associated with more infections. All patients who were ≥2 years old,...
5.
Neelapu S, Chavez J, Sehgal A, Epperla N, Ulrickson M, Bachy E, et al.
Blood
. 2023 Oct;
143(6):496-506.
PMID: 37879047
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) follicular lymphoma (FL). Approval was supported by the phase 2, multicenter, single-arm ZUMA-5...
6.
Murthy H, Zhang M, Chen K, Ahmed S, Deotare U, Ganguly S, et al.
Blood Adv
. 2023 Oct;
7(22):7007-7016.
PMID: 37792849
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT)...
7.
Ragon B, Shah M, DSouza A, Estrada-Merly N, Gowda L, George G, et al.
Blood Adv
. 2023 Feb;
7(12):2746-2757.
PMID: 36827681
The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and...
8.
Cook M, Dorris C, Makambi K, Luo Y, Munshi P, Donato M, et al.
Blood Adv
. 2022 Oct;
7(1):32-39.
PMID: 36260735
Relapsed/refractory primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL) are associated with short survival and represent an unmet need, requiring novel effective strategies. Anti-CD19 chimeric...
9.
Munshi P, Chen Y, Ahn K, Awan F, Cashen A, Shouse G, et al.
Transplant Cell Ther
. 2022 May;
28(8):487.e1-487.e7.
PMID: 35609865
Data for outcomes after autologous hematopoietic cell transplantation (auto-HCT) in diffuse large B-cell lymphoma (DLBCL) patients ≥70 years are limited. Auto-HCT is feasible in older DLBCL patients. Using the Center...
10.
Makhani S, Oza S, Reich-Slotky R, Munshi P, Biran N, Donato M, et al.
Transplant Cell Ther
. 2022 Mar;
28(6):306.e1-306.e7.
PMID: 35248777
Salvage autologous hematopoietic stem cell transplantation (HSCT) is an effective treatment for patients with relapsed multiple myeloma (MM). Peripheral blood stem cells (PBSCs), a source of hematopoietic stem cells (HSCs),...